Go Pro
NASDAQ:CDIO

Cardio Diagnostics (CDIO) Stock Price, News & Analysis

Cardio Diagnostics logo
$1.83 -0.01 (-0.54%)
As of 09/3/2026 04:00 PM Eastern

About Cardio Diagnostics Stock (NASDAQ:CDIO)

Advanced

Key Stats

Today's Range
$1.83
$1.93
50-Day Range
$1.55
$2.21
52-Week Range
$0.97
$7.91
Volume
89,781 shs
Average Volume
50,592 shs
Market Capitalization
$5.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Cardio Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

CDIO MarketRank™: 

Cardio Diagnostics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cardio Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cardio Diagnostics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cardio Diagnostics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cardio Diagnostics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cardio Diagnostics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cardio Diagnostics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cardio Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    1.10% of the float of Cardio Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cardio Diagnostics has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cardio Diagnostics has recently increased by 24.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cardio Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Cardio Diagnostics does not have a long track record of dividend growth.

  • News Sentiment

    Cardio Diagnostics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.
  • Search Interest

    1 people have searched for CDIO on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cardio Diagnostics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    8.99% of the stock of Cardio Diagnostics is held by insiders.

  • Percentage Held by Institutions

    8.06% of the stock of Cardio Diagnostics is held by institutions.

  • Read more about Cardio Diagnostics' insider trading history.
Receive CDIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDIO Stock News Headlines

A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.tc pixel
See More Headlines

CDIO Stock Analysis - Frequently Asked Questions

Cardio Diagnostics' stock was trading at $2.71 at the beginning of the year. Since then, CDIO stock has decreased by 32.5% and is now trading at $1.83.

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) released its earnings results on Friday, August, 7th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $0.01 million for the quarter. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative trailing twelve-month return on equity of 82.28%.

Shares of Cardio Diagnostics reverse split on Tuesday, May 13th 2025.The 1-30 reverse split was announced on Thursday, May 8th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of CDIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardio Diagnostics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), MSP Recovery (LIFW), NuCana (NCNA), Recursion Pharmaceuticals (RXRX), SoundHound AI (SOUN) and Caribou Biosciences (CRBU).

Company Calendar

Last Earnings
8/07/2026
Today
9/03/2026
Next Earnings (Estimated)
11/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CDIO
CIK
1870144
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.50 million
Net Margins
-43,133.33%
Pretax Margin
-43,126.66%
Return on Equity
-82.28%
Return on Assets
-76.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.16
Quick Ratio
17.16

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
541.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.51 per share
Price / Book
0.73

Miscellaneous

Outstanding Shares
2,960,000
Free Float
2,694,000
Market Cap
$5.42 million
Optionable
Not Optionable
Beta
2.28
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:CDIO) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners